Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496

NCT00898963 | Completed

• 2 other identifiers: CDR0000544400ECOG-E1496T1
• Study Type: observational
• Target: 175
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.

Conditions

Lymphoma

Keywords

stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage III grade 3 follicular lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; stage IV grade 3 follicular lymphoma

Outcome Measures

Primary Outcomes (4)

• Correlation of gene expression profiles with progression-free survival (PFS)

  1 month

• Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry

  1 month

• Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers

  1 month

• Correlation of relevant biomarkers with clinical features, response, and PFS

  1 month

Interventions

gene expression analysis GENETIC

microarray analysis GENETIC

polymorphism analysis GENETIC

diagnostic laboratory biomarker analysis OTHER

immunohistochemistry staining method OTHER

immunologic technique OTHER

Eligibility Criteria

• Age: 18 Years - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Samples submitted for research from patients participating in E1496

DISEASE CHARACTERISTICS: * Diagnosis of follicular lymphoma * Stage III or IV disease * Received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• ECOG-ACRIN Cancer Research Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Lymphoma; Lymphoma, Follicular

Interventions

Gene Expression Profiling; Microarray Analysis; Amplified Fragment Length Polymorphism Analysis; Immunohistochemistry; Immunologic Techniques

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Microchip Analytical Procedures; DNA Fingerprinting; Polymerase Chain Reaction; Nucleic Acid Amplification Techniques; Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques

Study Officials

• Randall D. Gascoyne, MD

  British Columbia Cancer Agency

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: April 18, 2007
• Primary Completion: February 11, 2011
• Study Completion: February 11, 2011
• Last Updated: July 31, 2020

Record last verified: 2020-07